Clinical Trial Update: Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating furmonertinib in EGFR-mutant, PD-L1 positive locally advanced or metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Fudan University | Conditions: Non-Small-Cell Lung Cancer | Phase 2 | Status: UNKNOWN